Craig Rouskey, MSc — Founder & CEO, Flore
Founder & CEO, Flore Inc. — MSc, Molecular Biology, Microbiology, Biochemistry & Immunology
Craig Rouskey is a microbiome scientist and the founder and CEO of Flore Inc., the company behind the original made-for-you probiotic. He has worked in gut microbiome science since 2005 — more than a decade before the word "microbiome" appeared on a probiotic label.
Background & training
Craig holds a Master of Science with graduate training in molecular biology, microbiology, biochemistry and immunology. His scientific career spans two decades of work at the intersection of metagenomic sequencing, immunology and applied probiotic formulation. He acquired and rebuilt Sun Genomics into Flore, shifting the company from a retail test-and-report model to a precision-formulation platform that manufactures a different probiotic for every individual based on their own gut data.
The work behind Flore's Central Intelligence
Under Craig's direction, Flore built what it calls its Central Intelligence: a formulation engine trained on nine years of paired data — real shotgun-metagenomic gut sequencing matched to documented symptom and tolerability outcomes. That body of work now spans tens of thousands of individual formulations, each compounded from a curated library of clinically selected probiotic strains and prebiotics.
- Designed systems that integrate microbiome sequencing, blood biomarkers and urinalysis into a single picture used to optimize each personalized formula.
- Oversaw a longitudinal real-world evidence program tracking how individual formulas change as a person's microbiome changes over time.
- Partnered with academic microbiome programs — including Arizona State University's Biodesign Institute — on peer-reviewed research into precision synbiotics.
Areas of expertise
- The human gut microbiome and metagenomic interpretation
- Probiotics and precision synbiotic formulation
- Precision and personalized medicine
- Immunology and biochemistry of host–microbe interactions
Selected research
Flore's science has been published in the peer-reviewed literature. Craig leads the company whose precision-synbiotic approach was evaluated in mSystems (American Society for Microbiology, 2024): "Precision synbiotics increase gut microbiome diversity and improve gastrointestinal symptoms in a pilot open-label study for autism spectrum disorder." See the full evidence base on the evidence page.
Build a formula from your gut dataThese statements have not been evaluated by the Food and Drug Administration. Flore products are not intended to diagnose, treat, cure, or prevent any disease.